Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease N. Harada (Kawasaki, Japan), K. Otsuka (Kawasaki, Japan), A. Horiuchi (Kawasaki, Japan), Y. Shinka (Kawasaki, Japan), H. Yamamura (Kawasaki, Japan), N. Miyao (Kawasaki, Japan)
Source: Virtual Congress 2020 – Investigations of COPD
Session: Investigations of COPD Session type: E-poster sessionNumber: 3276
Disease area: Airway diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Harada (Kawasaki, Japan), K. Otsuka (Kawasaki, Japan), A. Horiuchi (Kawasaki, Japan), Y. Shinka (Kawasaki, Japan), H. Yamamura (Kawasaki, Japan), N. Miyao (Kawasaki, Japan). Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease. 3276
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004
Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
In chronic obstructive pulmonary disease, a combination of ipratropium and long-acting beta2-agonists is more effective than either agent alone Source: Eur Respir J 2001; 18: Suppl. 33, 211s Year: 2001
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003
Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
The role of bronchodilator treatment in the prevention of exacerbations of COPD Source: Eur Respir J 2012; 40: 1545-1554 Year: 2012
Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008
Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002